Eficacia de la interleucina-2 recombinante (rIL-2) en pacientes con infección avanzada por VIH-1 y escasa respuesta inmunológica al TARGA OBJETIVO. Evaluamos la eficacia de la interleucina-2 recombinante (rIL-2) en pacientes infectados por VIH, con inmunodepresión avanzada y respuesta inmune discordante al tratamiento antirretroviral de gran actividad (TARGA). 3 (intervalo, 38-280) 18 meses después de la última dosis de rIL-2. Este aumento se asoció con una disminución en la expresión de los marcadores de activación linfocitaria, HLA-DR y CD38. CONCLUSIÓN. Estos resultados sugieren que la rIL-2, en pacientes con infección por VIH avanzada y respuesta inmune discordante al TARGA, puede contribuir a la expansión de los linfocitos CD4؉ a través de una disminución de la activación inmunológica.
Eficacia de la interleucina-2 recombinante (rIL-2) en pacientes con infección avanzada por VIH-1 y escasa respuesta inmunológica al TARGA
Introduction
A significant proportion of patients with advanced HIV-infection show incomplete immune reconstitution after initiation of highly active antiretroviral therapy (HAART) and may be at risk for opportunistic infections and clinical progression 1 . Several trials have shown that various schedules of recombinant interleukin-2 (rIL-2) in combination with HAART safely increase CD4+ cell counts in patients with relatively high baseline CD4+ -values [2] [3] [4] . Nevertheless, there is little data on the usefulness of rIL-2 in patients with advanced immune deficiency [5] [6] [7] [8] . Furthermore, the impact on repopulation of various T-cell subsets, the long-term outcome of these patients, and the mechanism of rIL-2-induced immune restoration have not been completely elucidated.
This study assesses the efficacy and safety of intermittent subcutaneous rIL-2 administration in a group of patients with chronic HIV-1 infection on stable HAART and CD4+ T-cell counts persistently less than 200/mm 3 despite undetectable plasma HIV-RNA.
Materials and methods

Study design
Nineteen Caucasian patients were enrolled in an open, prospective study from January 2001 to June 2003. Eligibility criteria included age 18 to 60 years, plasma HIV-RNA < 50 copies/mL, stable HAART, CD4+ < 200 cells/ mm 3 with no significant increase in the last 12 months, and no AIDS-defining illnesses or steroid administration for at least one year. Patients were scheduled to receive 6 cycles of subcutaneous rIL-2 (Macrolin  , Chiron, France), consisting of 4.5 × 10 6 IU daily for 5 consecutive days, every 4 weeks. Patients receiving at least one dose of rIL-2 were included in the safety analysis, based on changes in plasma HIV-RNA and laboratory parameters as well as clinical safety and tolerability. Blood samples for measuring plasma HIV-RNA, lymphocyte subset analysis, and T-cell production of intracellular cytokines were obtained on the first day of each cycle prior to dose administration, and one month after the last cycle. After completion of therapy, blood samples were obtained every three months. Efficacy was evaluated in patients receiving at least three cycles. The primary study endpoint was the median change in CD4+ lymphocyte counts at the end of treatment from baseline. Secondary endpoints were the percentage of patients who attained more than 200 CD4+ T-cells/mm 3 , changes in the percentage of lymphocyte phenotype subsets, assessment of intracellular IL-2, IFN-␥, IL-4 and TNF-␣ production, and the tolerance and safety of rIL-2 therapy.
Laboratory testing
Lymphocyte subpopulations were analyzed in lysed fresh whole blood samples by flow cytometry (FACScalibur; Becton Dickinson, San Jose, CA), and Cell-Quest software for acquisition and analysis. Intracellular production of IFN-␥, TNF-␣, IL-4 and IL-2 was detected by flow cytometry after stimulating whole blood samples with PMA and ionomycin during 4 h in the presence of monensin, plus further lysis, permeabilization and cell staining with specific monoclonal antibodies. Non-stimulated whole blood was used as a negative control.
Statistical analyses
The data set was closed on May 31, 2005. A paired Wilcoxon signed-rank test was used to assess whether changes over time were different from zero. Correlations were studied with the non-parametric Spearman correlation coefficient. A two-sided P-value less than 0.05 was considered statistically significant. Multivariate analysis was not performed because of the small number of patients. Data analysis was performed with SPSS, v. 12.0 (SPSS Inc.; Chicago, IL). All patients provided written informed consent for participation.
Results
Demographic and clinical characteristics of the patients are summarized in table 1.
Changes in CD4+ and CD8+ T lymphocytes
Overall, rIL-2 led to an increase in CD4+ T-cell counts from a median of 99 cells/mm 3 ) 18 months after the last dose (P < 0.001) (table 2). The CD4+ T-cell percentage increased from 10% (range, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] to 13% (range, 3-21) after the third cycle (P = 0.001) and remained stable afterwards (table 2) . However, an individual-based analysis of CD4+ T-cell count change over time showed marked heterogeneity. Among 18 patients receiving at least 3 cycles of rIL-2, 5 (27.7%) experienced an increase in CD4+ cell counts lower than 25%, and 3 (17%) (P = 0.50) and 8 (44%) (P = 0.016) patients achieved > 200 CD4+ lymphocytes/mm 3 at the end of treatment and at month 18 post-treatment, respectively. Pre-treatment CD4+ T-cell count differed significantly between patients who achieved > 200 CD4+ lymphocytes/mm 3 at the end of treatment (166 ± 46 cells/mm 3 ) and those who did not achieve this threshold (88 ± 26 cells/ mm 3 ; P = 0.001), whereas age, sex, HCV/HIV co-infection and a previous AIDS-defining event did not correlate with CD4+ T-cell count at treatment end. CD8+ T-cell percentage and absolute count remained stable during the study (table 2) .
Changes in T lymphocyte subpopulations
No statistically significant changes were observed in the percentage of naïve and memory CD4+ T-cells over time (table 2) . As T-cell counts increased during treatment, a significant increase in the absolute counts of both naive and memory CD4+ T-cells was observed at the end of treatment (data not shown). Notably, rIL-2 treatment led to a significant decrease in cell surface expression of HLA-DR and CD95 on CD4+ T-cells, and HLA-DR and CD38 on CD8+ T-cells (table 2) . Furthermore, there was an increase in the expression of the alpha-chain of IL-2 receptor (CD25) on CD4+ T lymphocytes, and the effector cell marker (CD28) on CD8+ T lymphocytes (table 2) . A trend toward a correlation was found between the HLA-DR expression rate on CD4+ T-cells and CD4+ T-cell counts at baseline (r = -0.30; P = 0.12), and between the decrease in HLA-DR expression on CD4+ T-cells and the increase in CD4+ T lymphocyte counts observed one month after the last dose, as compared to baseline (r = 0.345; P = 0.09).
Assessment of cytokine production
The percentage of IL-2-producing CD4+ T-cells increased from a median of 9.8% (range, 3.0-31) at baseline to 22.8% (range, 3.2-32.7) after the third cycle (P = 0.003) and 27% (range, 15.5-61.4) at the end of treatment (P = 0.005). Similarly, the percentage of IL-2-producing CD8+ T-cells significantly increased at the end of treatment as compared to baseline (P = 0.003). Intracellular expression of IFN-␥, TNF-␣ and IL-4 in both CD4+ and CD8+ T-cells remained unchanged during the study.
Safety
Mild constitutional symptoms and local erythema at the injection site occurred in all patients. Three patients discontinued treatment because of intolerance, one of them after the first dose, and two others after the third and the fifth cycle, respectively. Only one patient suffered severe side effects. In brief, after the third dose of the fifth cycle he was admitted to another hospital because of high fever (41°C), chest tightness and erythroderma. Oxygen and 6-methylprednisolone were administered, rIL-2 was definitively stopped, and he experienced a rapid clinical improvement. A transitory increase in HIV-RNA was seen in 50% of patients (9/18) during the treatment period.
Discussion
Overall, subcutaneous rIL-2 significantly increased both absolute count and percentage of the CD4+ lymphocyte pool. Our results confirm that rIL-2 might improve the immunological status of patients who start HAART with advanced HIV infection and persist with < 200 CD4+ lymphocytes/mm 3 , despite viral suppression to undetectable levels [5] [6] [7] [8] . However, in agreement with previous reports 9 , individual response to rIL-2 varied widely, and almost 30% (5/18) of patients receiving at least 3 cycles of rIL-2 had a minimal or null response (CD4+ T-cell increase Յ 25%). The lower percentage of patients who achieved 200 CD4+ T-cells/mm 3 in our study in comparison with previous reports [5] [6] [7] [8] may be related to a more advanced disease status in our population, as reflected by a lower CD4+ T-cell count at baseline (99 cells/mm 3 ) and the high rate of patients with a previous AIDS-defining clinical event (64%), or to the lower daily dose of rIL-2 administered in our study. We tried this dose, which provides the same accumulated monthly amount of rIL-2 as the standard dose, because lower daily doses of rIL-2 have been proven effective, are better tolerated, and allow for a better quality of life 5 . In keeping with previous studies, the treatment was in general well tolerated, yet one patient suffered a life-threatening event.
Poor immune reconstitution in HIV-infected patients on HAART has been related to low nadir CD4+ T-cell counts 10, 11 and markers of limited thymopoiesis, including older age, decreased thymic mass and smaller number of peripheral naïve CD4+ T-cells 12, 13 . Furthermore, persistent immune activation and spontaneous apoptosis were found to be a consistent feature in patients with a discordant immune response, supporting a role for immune activation in the pathogenesis of CD4+ T-cell depletion and immune reconstitution following HAART [14] [15] [16] . Several hypotheses such as cellular proliferation 17 , prevention of apoptosis 18 , and neo-thymic production 7 have been proposed to explain rIL-2-driven CD4 T-cell expansion, but the mechanisms are still not completely understood. Recently reported results suggest that intermittent rIL-2 leads to expansion of the CD4+ T-cell pool by downregulation of immune activation and T-cell proliferation rates 19 . Additionally, in vivo labeling studies of the CD4+ T-cell pool before and after rIL-2 therapy identified the emergence of a long-lived CD4+ T-cell subpopulation (CD4+ CD25+) on both naïve (CD45RA + CD27+) and recall memory phenotypes (CD45RO + CD27+) 20 . In vitro study has shown that IL-2 production and CD25 expression shape a population of regulatory T-cells (CD4+ CD25+ CD62+) that accounts for 1% to 2% of the entire CD4+ T-cell pool and plays an essential role in peripheral CD4+ T-cell homeostasis 21 . Loss of these regulatory cells has been associated with higher levels of immune activation and decreases in the number of peripheral CD4+ T-cells 22 . In keeping with these results, we observed a sustained increase of CD25 expression on CD4+ T-cells (although we did not further characterize them as regulatory cells) and a significant decrease in the expression of immune activation markers on both CD4+ and CD8+ T-cells. In addition, there was an increase in co-stimulatory molecule CD28 expression on CD8+ lymphocytes, which also suggests a decreased immune activation state. It has been shown that CD8+ T-cells lacking CD28 surface expression represent a subset of short-lived activated and differentiated cytotoxic effector cells, driven by viral replication 23 . Indeed, the percentage of both CD4+ and CD8+ T-cells expressing intracellular IL-2 did increase significantly.
Interestingly, immunological recovery continued in our study after rIL-2 was discontinued. This long-lasting effect has been observed in patients with advanced HIV infection 5, 7 and can be explained by the persistence of rIL-2-driven homeostatic changes.
The main limitation of our study is the lack of a control group. The immunological improvement could be explained alternatively by persistent HAART-induced viral suppression 24 , which could be related to a slow but ongoing decay in viremia over time. Another potential limitation is the small size of the population studied. Assessment of T lymphocyte subpopulation changes over time was only performed in a subset of patients. This fact could explain the lack of significant changes in naïve and memory CD4+ T-cell percentages, as well as the lack of a significant correlation between the CD4+ T-cell count increase and decreased expression of immune activation markers. Finally, although the use of rIL-2 makes particular sense in patients with advanced infection such as those included in our study, its clinical benefit in this subpopulation has yet to be definitively proven.
In summary, although high interindividual variability was observed, our data suggest that rIL-2 therapy might expand the CD4+ T-cell pool in some patients with advanced disease and a blunted immune response to HAART. These rIL-2-driven changes could be mediated by down-regulation of immune activation status.
The results of the ongoing SILCAAT trial will determine whether the changes in the number and function of rIL-2-induced CD4+ T-cells translate into clinical benefit.
